Goncalves Joana 4

4 · Oruka Therapeutics, Inc. · Filed Jan 16, 2026

Form 4

Period: 2026-01-15

Chief Medical Officer

Transactions

Exercise/Conversion
Common Stock
2026-01-15$6.84/sh+3,500$23,940→ 5,018 total
Exercise/Conversion
Common Stock
2026-01-15$7.80/sh+3,500$27,300→ 8,518 total
Sale
Common Stock
[F1][F2]
2026-01-15$31.56/sh−4,381$138,276→ 4,137 total
Sale
Common Stock
[F1][F3]
2026-01-15$32.24/sh−2,619$84,429→ 1,518 total
Exercise/Conversion
Employee Stock Option (right to buy)
[F4]
2026-01-15−3,500→ 221,563 total
Exercise: $6.84Exp: 2034-05-06→ Common Stock (3,500 underlying)
Exercise/Conversion
Employee Warrant (right to buy)
[F5]
2026-01-15−3,500→ 192,992 total
Exercise: $7.80Exp: 2034-07-14→ Common Stock (3,500 underlying)

Footnotes (5)

[F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.86 to $31.85, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.86 to $32.71, inclusive.
[F4]The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.
[F5]The warrant vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.

Signature

/s/ Paul Quinlan, as attorney-in-fact for Joana Goncalves|2026-01-16

Documents

1 file